CS
CODX

Credit Suisse’s Co-Diagnostics CODX Stock Holding History

Credit Suisse’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-621
Closed -$177K – 4472
2021
Q1 		$177K Sell
621
-165
-21% -$65.9K ﹤0.01% 4147
2020
Q4 		$218K Buy
786
+308
+64% +$114K ﹤0.01% 4072
2020
Q3 		$194K Sell
478
-51
-10% -$26.2K ﹤0.01% 3836
2020
Q2 		$307K Sell
529
-68
-11% -$31K ﹤0.01% 3579
2020
Q1 		$136K Buy
+597
New +$104K ﹤0.01% 3757

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Credit Suisse's CODX Position: Q2 2021 in Review

Credit Suisse sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 621 shares — an estimated $177K sold.

Credit Suisse first reported a position in CODX in Q1 2020 and held it in 5 quarters. The position peaked at $307K in Q2 2020. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

  • Credit Suisse reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
  • Credit Suisse sold 621 Co-Diagnostics shares in Q2 2021, an estimated $177K.
  • Credit Suisse first reported a position in Co-Diagnostics in Q1 2020 and held it in 5 quarters.
  • Credit Suisse's Co-Diagnostics position peaked at $307K in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.